Direct-to-Consumer Blood Tests Leave Patients Searching for Answers

Companies including Oura, Function Health, and Hims & Hers are selling direct-to-consumer blood tests priced between $99 and a few hundred dollars, allowing patients to order testing without a doctor's referral. The trend has created a gap where consumers receive results but lack clinical guidance to interpret them or decide on next steps.

Oura, which has sold 5.5 million smart rings, began offering blood tests for $99 through partnerships with Quest Diagnostics in early 2026. Function Health received a $2.5 billion valuation after a recent funding round and offers testing to hundreds of thousands of members. Hims & Hers, with 2.5 million members, launched a blood-testing product in late 2025. Labcorp OnDemand and Quest also offer direct ordering without physician referral.

Lana McDonald, a 34-year-old teacher from Massachusetts, ordered an Oura blood test after receiving a promotional email. Eight of her results came back out of range, including high cholesterol and low hemoglobin, but the results included no explanation. McDonald used Google to research what the values meant, then ordered an additional ferritin test directly from Quest. When she uploaded her results to her primary care physician through a patient portal, she was told to schedule an appointment—a wait that stretched two months.

Dr. Jeffrey Linder, chief of general internal medicine at Northwestern University's Feinberg School of Medicine, said in an email that patients are increasingly bringing outside test results to appointments asking physicians to interpret them. Dr. Anna Wexler, an assistant professor of Medical Ethics and Health Policy at the University of Pennsylvania, noted that while "more information is better" appeals to health-conscious consumers, it can leave patients confronting abnormal results without context or knowing whether action is needed.

Oura and Function Health employ third-party clinician partners to interpret results and call patients with critical findings. Dr. Ricky Bloomfield, chief medical officer at Oura, said the blood test product is intended to complement—not replace—an ongoing relationship with a health care provider. However, Wexler raised concerns about accountability when companies contract with physician groups, saying there are "real questions of liability and accountability" when a company claims it is merely a platform connecting patients to doctors.

Context

The direct-to-consumer blood-testing market has grown as wearable technology and health apps expanded. Previously, blood testing was typically initiated by a physician who would order tests, receive results, and discuss findings with the patient. This model centered clinical interpretation within an established provider-patient relationship where a doctor understood a patient's medical history and could contextualize abnormal values.

The shift reflects broader consumer interest in health metrics and preventive monitoring. Wearable devices like Oura rings track sleep, heart rate, and other biometric data, positioning companies to market additional health services to engaged user bases. The pricing—$99 for Oura's initial offering—positions direct testing as affordable compared to traditional lab visits that often require insurance or out-of-pocket costs of $200 to $500 depending on which tests are ordered.

What's Next

As these platforms expand, the gap between test availability and clinical guidance will likely become a regulatory and liability issue. Patients will continue bringing results to primary care physicians, creating additional appointment demand and potentially delaying care decisions while waiting for physician availability. The key tension ahead is whether companies will be required to provide more robust clinical support as part of their offerings, or whether the responsibility for interpretation will remain with individual patients and their existing providers. Oura and Function Health's emphasis on physician partnerships suggests they are aware of this pressure, but the two-month wait McDonald experienced indicates that existing primary care infrastructure may not absorb this new volume of patient-initiated testing without systemic changes.